Underserved PCOS Market Neuraura targets a large, underserved portion of women with PCOS, aiming to provide an over‑the‑counter, affordable device that treats insulin resistance and other PCOS aspects rather than only masking symptoms, presenting a clear opening for early market penetration and advocacy from medical professionals and patient groups.

Regulatory Pathway The initial market entry leverages a predicate regulatory code (NUH) under FDA 510(k), suggesting a faster regulatory route and potential for earlier revenue with a plan to progressively expand device claims to broader PCOS treatment applications.

Clinical & Data Expansion Planned small‑scale clinical studies and user data collection indicate an opportunity to build evidence supporting expanded indications toward insulin resistance, pre‑diabetes, and diabetes, which can be leveraged in payer discussions and premium device propositions.

Affordability & Access Positioning as an affordable, widely accessible device opens channels for direct consumer sales, major pharmacy or retailer partnerships, and telehealth or digital health collaborations to reach a broad audience with potential for high-volume adoption.

Strategic Levers As a lean, early‑stage company with limited revenue but targeted funding, there is a sales opportunity to pursue partnerships with larger medical equipment distributors, gynecology and endocrinology clinics, as well as potential co‑development or licensing deals to scale manufacturing and distribution.